SHENZHEN, China and SAN JOSE, Calif., July 2, 2019 — MGI expressed confidence in its core patent portfolio in gene sequencing and vowed to fully support the industry in achieving higher quality, more cost-effective sequencing.
With leading products and services, MGI has gained support from users in every country where it has launched. The company will continue to help customers access high-quality and cost-efficient sequencing solutions. MGI has taken legal action to protect its intellectual property in response to claims filed by Illumina and will continue to do so as necessary.
MGI is committed to developing and producing advanced gene sequencing instruments, consumables, and reagents, and to fostering the industry’s progress. As one of the three companies worldwide capable of mass-producing high-throughput sequencers, MGI has invested more than 5 billion RMB in R&D to build its sequencing technology patent portfolio. Through continuous efforts, MGI is bringing greater choice to genomics markets worldwide.
MGI opposes the abuse of patent litigation to maintain market monopoly and suppress industry development, and advocates fair competition and an open environment for innovation.
